Ligand Pharmaceuticals (LGND) Raw Materials (2023 - 2024)
Ligand Pharmaceuticals recorded quarterly Raw Materials of $603000.0 in Q4 2024, down 75.83% quarter-over-quarter from $2.5 million in Q3 2024, and up 43.57% year-over-year from $420000.0 in Q1 2024.
Ligand Pharmaceuticals' Raw Materials history runs 2 years deep, the most recent figure standing at $603000.0 for Q4 2024.
- In Q4 2024, Raw Materials rose 43.57% year-over-year to $603000.0; the TTM figure through Dec 2024 stood at $603000.0 (up 43.57% YoY), while the FY2024 annual figure was $603000.0, up 43.57% from the prior year.
- Raw Materials came in at $603000.0 for Q4 2024 at Ligand Pharmaceuticals, down from $2.5 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $2.5 million in Q3 2024 to a low of $420000.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 603,000.00 |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Dec 31, 2023 | 420,000.00 |